Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fulcrum Therapeutics Inc.

http://www.fulcrumtx.com/

Latest From Fulcrum Therapeutics Inc.

Finance Watch: Third Harmonic Attempts A Flight Through The IPO Window

Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.

Financing Business Strategies

Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation

GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal. 

Financing Innovation

Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint

The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.

Rare Diseases FDA

Deal Watch: Roche Partners With Jnana On Cellular Metabolism Approach To Disease

Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Fulcrum Therapeutics Securities Corp.
UsernamePublicRestriction

Register